Overview of clinical outcome and therapeutic effectiveness of Favipiravir in patients with COVID-19 admitted to intensive care unit, Riyadh, Saudi Arabia

Mutair, Abbas Al; Shamou, Jinan; Alhumaid, Saad; Layqah, Laila; Ahmad, Gasmelseed Y.; Koritala, Thoyaja; Mohaini, Mohammed Al; Almahmoud, Sana; Barry, Mazin; Khan, Amjad; Dhama, Kuldeep; Al-Jamea, Lamiaa H.; Woodman, Alxeander; Rabaan, Ali A.

doi:10.1016/j.jiph.2022.01.013

Cited by 10 publications

(11 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a multicenter randomized clinical trial with a small number of patients, FVP and CLQ were compared, and no significant difference was found in terms of LOHS (Dabbous et al 2021 ). Another multicenter retrospective cohort study compared COVID-19 patients who had and had not received FVP therapy in terms of hospital and ICU stays, a significant decrease was found in the FVP group (Mutair et al 2022 ). In a multicenter randomized clinical trial comparing FVP and lopinavir + ritonavir, no significant difference was reported in terms of LOHS (Solaymani-Dodaran et al 2021 ).…”

Section: Discussionmentioning

confidence: 99%

Evaluation of the relationship of treatment and vaccination with prognosis in patients with a diagnosis of COVID-19

Oncu,

Korkmaz

2024

Inflammopharmacol

View full text Add to dashboard Cite

Purpose Coronavirus disease 2019 (COVID-19) has affected millions of people worldwide and caused mortality. Many factors have been reported to affect the prognosis of COVID-19. In this study, we aimed to investigate the effects of drug therapy and vaccination on prognosis in patients hospitalized with a COVID-19 diagnosis. Methods In this single-center, cross-sectional study, data were retrospectively collected from patients receiving inpatient treatment at a university hospital with a diagnosis of COVID-19 between January 1, 2020, and April 30, 2022. The patients’ demographic and clinical characteristics were recorded. The Chi-square, Cox and logistic regression was performed, P < 0.05 was considered statistically significant. Results Total 1723 patients (50.1% were men, mean age: 60.6 ± 16.90) who had not been vaccinated rate was 27.0% (> 3 doses: 45.7%). Mortality rate was 17.0%. Increasing age, male, a high Charlson Comorbidity Index (CCI), and no vaccination significantly increased mortality (P < 0.05). The mortality rate was significantly lower in the chloroquine treatment group than in the other treatment groups. Increasing age, male, and a high CCI were determined to be factors that significantly increased the length of hospital stay (LOHS). LOHS found to be significantly lower in the favipiravir or chloroquine groups compared to the remaining treatment groups (P < 0.001). Both mortality and the LOHS significantly differed according to AST, d-dimer, ferritin, and GFR. Conclusion This study primarily investigated the effect of treatment and vaccination on the prognosis of COVID-19. This was determined to be prepared for another potential pandemic that may arise due to COVID-19.

show abstract

Section: Discussionmentioning

confidence: 99%

Evaluation of the relationship of treatment and vaccination with prognosis in patients with a diagnosis of COVID-19

Oncu,

Korkmaz

2024

Inflammopharmacol

View full text Add to dashboard Cite

show abstract

“…Many antiviral drugs and monoclonal antibodies were authorized for COVID-19 in persons who are more prone to get severely ill. The efficacy of favipiravir against several viral infections has emerged as possible therapy for COVID-19 [29]. The pharmacokinetic profile of favipiravir is quite complex [30].…”

Section: Discussionmentioning

confidence: 99%

Does the Ethnic Difference Affect the Pharmacokinetics of Favipiravir? A Pharmacokinetic Study in Healthy Egyptian Volunteers and Development of Level C In-vitro In-vivo Correlation

2023

View full text Add to dashboard Cite

Favipiravir is an antiviral drug used to treat influenza and is also being investigated for the treatment of SARS-CoV-2. Its pharmacokinetic profile varies depending on ethnic group. The present research examines the pharmacokinetic features of favipiravir in healthy male Egyptian volunteers. Another goal of this research is to determine the optimum dissolution testing conditions for immediate release tablets. In vitro dissolution testing was investigated for favipiravir tablets in three different pH media. The pharmacokinetic features of favipiravir were examined in 27 healthy male Egyptian volunteers. The parameter “AUC0-t” vs. percent dissolved was used to develop level C in vitro in vivo correlation (IVIVC) to set the optimum dissolution medium to achieve accurate dissolution profile for favipiravir (IR) tablets. The in vitro release results revealed significant difference among the three different dissolution media. The Pk parameters of twenty-seven human subjects showed mean value of Cpmax of 5966.45 ng/mL at median tmax of 0.75 h with AUC0-∞ equals 13325.54 ng.h/mL, showing half-life of 1.25 h. Level C IVIVC was developed successfully. It was concluded that Egyptian volunteers had comparable Pk values to American and Caucasian volunteers, however they were considerably different from Japanese subjects. AUC0-t vs. % dissolved was used to develop level C IVIVC to set the optimum dissolution medium. Phosphate buffer medium (pH 6.8) was found to be the optimum dissolution medium for in vitro dissolution testing for Favipiravir IR tablets.

show abstract

“…Many antiviral drugs and monoclonal antibodies were authorized for COVID-19 in persons who are more prone to get severely ill. The e cacy of favipiravir against several viral infections has emerged as possible therapy for COVID-19 [29]. The pharmacokinetic pro le of favipiravir is quite complex [30].…”

Section: Discussionmentioning

confidence: 99%

Does the Ethnic Difference Affect the Pharmacokinetics of Favipiravir? A Pharmacokinetic Study in Healthy EgyptianVolunteers and Development of Level C In-vitro In-vivo Correlation

Bendas

Rezk

Badr³

2022

Preprint

View full text Add to dashboard Cite

Background and Objective Favipiravir is an antiviral drug used to treat influenza. It is also being investigated for the treatment of a variety of other viral diseases, including SARS-CoV-2. Its pharmacokinetic profile varies depending on ethnic group. The present research examines the pharmacokinetic (Pk) features of favipiravir in healthy male Egyptian volunteers. Another goal of this research is to determine the optimum dissolution testing conditions for immediate release (IR) tablets.Methods In vitro dissolution testing was investigated for favipiravir tablet, Avigan® 200 mg tablets, in three different pH media. The pharmacokinetic (Pk) features of favipiravir were examined in healthy male Egyptian volunteers. A newly developed and validated LC-MS/MS method was used to analyze real plasma samples of the healthy volunteers. Level C in vitro in vivo correlation (IVIVC) was developed to set the optimum dissolution medium to achieve accurate dissolution profile for favipiravir (IR) tablets.Results In vitro dissolution results revealed significant difference among the three different dissolution media. The Pk parameters of twenty-seven human subjects showed mean value of Cp max of 5966.45 ng/mL at median tmax of 0.75 h with AUC0-∞ equals 13325.54 ng.h/mL, showing half-life of 1.25 h. AUC0-t vs. % dissolved was used to develop level C IVIVC for favipiravir (IR) tablets.Conclusions When compared to American and Caucasian volunteers, Egyptian participants had comparable Pk values, however they were considerably different from Japanese subjects. Phosphate buffer medium (pH 6.8) was found to be the optimum dissolution medium for in vitro dissolution testing for Favipiravir IR tablets.

show abstract

Overview of clinical outcome and therapeutic effectiveness of Favipiravir in patients with COVID-19 admitted to intensive care unit, Riyadh, Saudi Arabia

Cited by 10 publications

References 55 publications

Evaluation of the relationship of treatment and vaccination with prognosis in patients with a diagnosis of COVID-19

Evaluation of the relationship of treatment and vaccination with prognosis in patients with a diagnosis of COVID-19

Does the Ethnic Difference Affect the Pharmacokinetics of Favipiravir? A Pharmacokinetic Study in Healthy Egyptian Volunteers and Development of Level C In-vitro In-vivo Correlation

Does the Ethnic Difference Affect the Pharmacokinetics of Favipiravir? A Pharmacokinetic Study in Healthy EgyptianVolunteers and Development of Level C In-vitro In-vivo Correlation

Contact Info

Product

Resources

About